Sirio Pharma (300791) — Free Cash Flow Generation Index

Latest as of June 2023: 0.41x

Sirio Pharma (300791) has a Free Cash Flow Generation Index of 0.41x as of June 2023. Free cash flow of CN¥41.96 Million represents 0% of operating cash flow (CN¥101.61 Million). See working capital to net assets of Sirio Pharma to evaluate short-term liquidity relative to the company's equity base.

FCF Generation Index

0.41x
Free Cash Flow / Operating CF

Free Cash Flow

CN¥41.96 Million
CNY

Operating Cash Flow

CN¥101.61 Million
CNY

Capital Expenditures

CN¥59.65 Million
CNY

Sirio Pharma Free Cash Flow Generation Index (2017–2024)

Historical FCF Generation Index trend for Sirio Pharma across 8 annual periods. Explore Sirio Pharma cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

Annual Free Cash Flow Generation for Sirio Pharma (2017–2024)

Year-by-year Free Cash Flow Generation Index for Sirio Pharma. For the full company profile including market capitalisation, see Sirio Pharma market cap and net worth.

Year FCG Index Free Cash Flow (CNY) Operating CF Capital Expenditures YoY Change
2024 0.27x CN¥154.84 Million CN¥566.97 Million CN¥412.13 Million ▲ +260.7%
2023 -0.17x CN¥-65.62 Million CN¥386.08 Million CN¥451.70 Million ▼ -150.0%
2022 0.34x CN¥151.17 Million CN¥444.86 Million CN¥293.69 Million ▲ +163.3%
2021 -0.54x CN¥-183.31 Million CN¥341.38 Million CN¥524.68 Million ▼ -278.0%
2020 0.30x CN¥96.43 Million CN¥319.57 Million CN¥223.14 Million ▲ +8.0%
2019 0.28x CN¥64.71 Million CN¥231.60 Million CN¥166.90 Million ▲ +191.7%
2018 -0.30x CN¥-55.87 Million CN¥183.46 Million CN¥239.32 Million ▲ +86.4%
2017 -2.24x CN¥-110.47 Million CN¥49.35 Million CN¥159.82 Million
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).